Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children
NCT ID: NCT01139905
Last Updated: 2015-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
24 participants
INTERVENTIONAL
2010-04-30
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lopinavir (LPV) Dose Reduction
NCT01159275
Lopinavir/Ritonavir Monotherapy in Children
NCT00626301
Dose Reduction of Lopinavir in Children
NCT00887120
TDM of Generic Lopinavir/Ritonavir 200/50 mg
NCT00802334
A PK and Salvage Study for Children With HIV-infection
NCT00476359
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour
lopinavir/ritonavir
standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lopinavir/ritonavir
standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age \< 18 years old
3. BW \> 25 kg
4. HIV RNA viral load \< 50 copies within 6 months
5. Written informed consent
Exclusion Criteria
2. Relevant history or current condition, illness that might interfere with drug absorption, distribution, metabolism or excretion.
3. Use of concomitant medications that may interfere with the pharmacokinetics of lopinavir/ritonavir
1 Year
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chulalongkorn University
OTHER
Radboud University Medical Center
OTHER
The HIV Netherlands Australia Thailand Research Collaboration
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kiat Ruxrungtham, MD
Role: PRINCIPAL_INVESTIGATOR
The HIV Netherlands Australia Thailand Research Collaboration
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HIV-NAT
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Klinklom A, Puthanakit T, Gorowara M, Phasomsap C, Kerr S, Sriheara C, Ananworanich J, Burger D, Ruxrungtham K, Pancharoen C. Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents. Antivir Ther. 2012;17(2):283-9. doi: 10.3851/IMP1958. Epub 2011 Nov 10.
Related Links
Access external resources that provide additional context or updates about the study.
HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HIV-NAT 100
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.